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Homozygosity mapping was performed in ﬁve patients from a consanguineous family who presented with infantile mitochondrial
encephalomyopathy attributed to isolated NADH:ubiquinone oxidoreductase (complex I) deﬁciency. This resulted in the identiﬁcation
of amissensemutation in a conserved residue of theC6ORF66 gene, which encodes a 20.2 kDamitochondrial protein. Themutation was
also detected in a patient who presented with antenatal cardiomyopathy. In muscle of two patients, the levels of the C6ORF66 protein
and of the fully assembled complex I were markedly reduced. Transfection of the patients’ ﬁbroblasts with wild-type C6ORF66 cDNA
restored complex I activity. These data suggest that C6ORF66 is an assembly factor of complex I. Interestingly, the C6ORF66 gene
product was previously shown to promote breast cancer cell invasiveness.Introduction
Congenital disorders of the mitochondrial respiratory
chain are common inborn errors of metabolism with an
incidence of 1:5000–8000 live births.1,2 Among these, iso-
lated NADH:ubiquinone oxidoreductase (complex I) deﬁ-
ciency (MIM 252010) is the most frequently diagnosed,
accounting for one-third of all cases of respiratory-chain
deﬁciency.3 Complex I is the largest and most intricate
of the ﬁve mitochondrial respiratory-chain complexes. It
comprises 45 proteins, of which seven are encoded by
the mitochondrial DNA (mtDNA) and the rest by the nu-
clear genome.4 Mutations in mtDNA genes were detected
in only 20% of the children with complex I deﬁciency,5,6
suggesting that the vast majority of patients with isolated
complex I deﬁciency suffer from mutations in nuclear
genes encoding complex I structural subunits or assembly
factors. Heretofore extensive sequence determination of
candidate genes revealed mutations in ten structural-sub-
units genes (reviewed in7) and in two assembly factors of
complex I, NDUFA12L and the human NDUFAF1.8,9 None-
theless, molecular diagnosis is still lacking for more than
50% of the patients.10 It is believed that their primary mo-
lecular defects reside in as-yet-unknown assembly factors.
The present report is the result of our endeavor to identify
new players in complex I biogenesis by using homozygos-
ity mapping in 20 consanguineous families of patients
with isolated complex I deﬁciency.
Material and Methods
Subjects
Five patients originating from a consanguineous family of Arab-
Muslim origin (Figure 1) were the subjects of this study. An addi-32 The American Journal of Human Genetics 82, 32–38, January 200tional four patients had a similar course, but tissues for enzymatic
and molecular studies were unavailable.
All the patients were born at term, and their birth weights were
appropriate for their ages; fetal movements were invariably re-
ported to be normal. All presented soon after birth with severe
metabolic acidosis and very high plasma-lactate levels (peak level:
38 mM, normal values < 2.2 mM). Patients F528, UA3, and UA4
died at 2–5 days of intractable acidosis. Patients who survived lon-
ger were repeatedly admitted because of exacerbation of the acido-
sis during intercurrent infections. Generalized muscle hypotonia
was noted soon after birth, and failure to thrive, irritability, pau-
city of spontaneous movements, dystonic posturing during cry-
ing, nystagmus, failure to interact with the surroundings and lack
of eye contact were evident at 6 months. Patient F511, who was
still alive at 16 months of age, had spastic tone with quadriplegic
involvement, thoracic kyphosis, and reduced range of motion at
the knees and hips. The pupillary response to light was sluggish,
and the patient failed to follow moving objects. Fundoscopy was
normal. No reaction to auditory stimuli could be elicited, and the
auditory-brain-stem-evoked response was bilaterally extinguished
except for a normal ﬁrst wave. The physical examination of the
oldest surviving patient, F334, at 7 years, was similar, with kypho-
sis and multiple contractures. The resting tone was increased with
a windswept appearance; the tendon reﬂexes were brisk. There was
no reaction to external stimuli, and intermittent irritability was
present. Reﬂex eye movements were normal, the pupil reaction
to light was sluggish, and examination of the fundi revealed bilat-
eral optic atrophy.
Generalized tonic-clonic convulsions occurred in two patients
during a decompensation episode, but persistent seizure disorder
was not part of the clinical picture. Echocardiography was normal
throughout infancy and early childhood in all but patient F528, in
whom severe cardiomyopathy was detected at 1 day of age. No ev-
idence of liver, renal, or hematological involvement was detected
in any of the patients.
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expired at 9–18 months of age of exacerbation of their persistent
acidosis. Patients F72, UA1, and UA2, who were not treated, died
at the same age.
Brain MRI of patient F511 at 16 months of age revealed severe
atrophy of both gray and white matter, with demyelination,
most prominent at the anterior aspects of the brain, leaving a
cortical ribbon. At the occipito-parietal region there were subven-
tricular cysts, emphasizing the ventricular walls. The cerebellum,
basal ganglia, pons, and medulla were severely atrophic (Figure 2).
Methods
Fibroblast cultureswereobtained fromforearmskinbiopsies. Tissue
cultures were grown in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) containing 4.5 g/L glucose, supplemented with 10% fetal
calf serum, 50 mg/ml uridine, and 110 mg/ml pyruvate at 37C in an
atmosphere of 5% CO2.
The Enzymatic Activities
The enzymatic activities of the mitochondrial respiratory-chain
complexes in mitochondria isolated from muscle and ﬁbroblasts
were determined as previously described.11
Complex I Assembly
Complex I assembly was studied in lauryl-maltoside-solubilized
muscle mitochondria by blue-native 5%–15% gradient acrylamide
gel electrophoresis.12 Gel-density analysis was performed by
ImageJ software.
Homozygosity Mapping
Genomic DNAwas extracted frommuscle or ﬁbroblasts of patients
who suffered infantile encephalomyopathy with variable cardio-
myopathy associated with isolated complex I deﬁciency. These pa-
tients originated from 20 consanguineous families, and DNA was
also extracted from the blood samples of their parents and healthy
sibs. The patients’ DNA was analyzed with Affymetrix Human
Mapping 50K SNP Array Xba240 as previously described,13
whereas their relatives’ DNAwas only genotyped for relevant poly-
morphicmicrosatellite markers. All experiments involving DNA of
the patients, their relatives, healthy controls, and patients’ cells
were approved by the Hadassah Ethical Review Committee (#26-
160905) and by the Supreme Helsinki committee of the Israeli
Ministry of Health (#920050420).
Figure 1. The Family Pedigree
Patients’ symbols are filled. Numbered sym-
bols represent individuals whose DNA sam-
ples were available for analysis. UA1–UA4
refer to patients whose DNA was unavail-
able but who were mentioned in the text.
Wild-Type cDNA Transfection
C6ORF66 cDNA was cloned into the
pLenti6/V5-D-TOPO 6969 bp expression
vector by directional TOPO cloning
(primers available upon request). The re-
combinant vector was propagated in One
Shot Stbl3 E. coli and introduced into
293FT cells after cotransfection with pLP1,
pLP2, and pLP/VSVG plasmids according
to the manufacturer’s instructions (Vira-
Power, Invitrogen). Patient cells were in-
fectedwith the lentiviral construct, and sta-
bly transduced cells were established by
blasticin selection.
C6ORF66 mRNA Quantification
Total RNA, isolated fromthepatients’ ﬁbroblasts,was reversed tran-
scribedandquantiﬁedby real-timePCR.Calibrationcurveswere es-
tablished by serial dilutions of two plasmids containing a cDNA in-
sert of either beta-actin orC6ORF66 and used to determine the ratio
of the two transcripts. TaqMan detection reagent was used for the
detection of beta-actin and SYBR green for the C6ORF66 (primers
available upon request).
Isolation of Subcellular Fractions
Mitochondrial and cytosolic fractionswere obtained through a dif-
ferential centrifugation protocol according to the method de-
scribed by Palacino et al.14 The purity of the subcellular fractions
was conﬁrmed by using the speciﬁc marker antibodies alpha-
Tubulin (cytosol) and pyruvate dehydrogenase (PDH) E1-alpha
(mitochondria).
Western-Blot Analysis
Subcellular fractions (12–50 mg total protein/lane)were resolved on
12% SDS-PAGE gels and transferred onto an Immobilon-P Transfer
membrane (Millipore, Bradford, Pennsylvania). Western-blot anal-
ysis was performed with anti-C6ORF66 (raised against a highly pu-
riﬁed C6ORF66 protein that was cloned in our lab; the antibodies
were prepared by Sigma-Aldrich, Israel), anti-alpha-Tubulin (Sero-
tec, Oxford, UK), and anti-PDH-E1-alpha (Molecular Probes,
Eugene, Oregon) antibodies at 1:2000, 1:20,000, 1:5,000 dilution,
respectively, to identify the proteins. Western-blot analysis of the
mitochondrial fractions from muscle of two control individuals
and two patients (F434 and F359) were studied in triplicates.
Density analysis was done with ImageJ software.
Results
All nine patients in this pedigree presented immediately
after birth with severe metabolic acidosis and very high
plasma-lactate levels (peak level: 38 mM, normal values <
2.2 mM). Three patients died during the ﬁrst week of in-
tractable acidosis, and the rest suffered from recurrent
exacerbations of the acidosis. Patients who survived devel-
oped severe encephalopathy, which was already evident atThe American Journal of Human Genetics 82, 32–38, January 2008 33
4–6 months of age. Severe cardiomyopathy was present
in only one patient, but other extracerebral systems were
unaffected. The oldest surviving patient was 7 years of age
at the time of the study.
The enzymatic activity of complex I in isolated mito-
chondria from muscle of the ﬁve patients who were ana-
lyzed in our laboratory was reduced to an average of
12.15% of the control mean (range: undetectable to 21%),
whereas in ﬁbroblasts of four patients, complex I activity
was reduced to an average of 46% (range: 32%–67%).
The other complex activities were normal in muscle and
ﬁbroblasts, with the exception of elevation of complex II
activity in muscles of three patients and mild reduction
of complex V in muscle of two patients (Table 1).
The blue-native sodium gel electrophoresis disclosed re-
duced abundance of the mature complex I to 30% of the
control. Two smaller intermediates, whichwerenot present
in the control lane, were additionally observed (Figure 3).
To identify the defective gene in this family, we have
ﬁrst determined the sequence of the seven mitochon-
drial-encoded genes and the ten genes that were previously
reported to be mutated in patients with isolated complex I
deﬁciency (NDUFS1, NDUFS2, NDUFS3, NDUFS4,
NDUFS6, NDUFS7, NDUFS8, NDUFV1, NDUFV2, and
NDUFA12L). No mutations were identiﬁed in these genes
in any of the patients.
Figure 2. Brain MRI of Patient F511 at
16 Months of Age
Axial (A) and coronal (B) T1 weighted im-
age showing severe atrophy of both gray
and white matter, with demyelination,
most prominent at the anterior aspects of
the brain, leaving a cortical ribbon. Sub-
ventricular cysts at the occipito-parietal
region emphasize the ventricular walls.
Mid-sagittal and axial images (C and D)
show severe atrophy of the cerebellum,
pons, and medulla.
Homozygosity mapping revealed
four stretches of homozygous SNPs
larger than 3.0 Mb in the DNA of
patient F334 (chromosome 6: 92.12–
102.27 Mb, chromosome 8: 134.3–
143.9 Mb, chromosome 4: 86.69–
90.5 Mb, and chromosome 5:
109.01–112.02 Mb). In the DNA of
patient F511, 12 homozygous regions
larger than 3 Mb were detected,
including chromosome 6: 90.02–
106.85 Mb. The two patients shared
an identical haplotype over a 10 Mb
region of chromosome 6: 92.12–
102.27 Mb. All the available DNA
samples were examined for the haplo-
type of four markers that spanned the region: D6S300,
rs9373985, D6S1606, and D6S1717. Because patient F72
was heterozygous for D6S1717 at 99.77Mb and the healthy
individual 2313 had an identical genotype to that of the
patients for rs9373985 at 97.17Mb, the critical region could
be narrowed down to a 2.6 Mb on chromosome 6 (97.17–
99.77 Mb).
We initially prioritized the seven open reading frames
within this interval according to the presence of their or-
thologs in species that are known to express complex I
activity. Only KLHL32 complied with this criteria; its or-
thologs were present in the genomes of the aerobic yeasts
Y. lipolytica and D. Hansenii, which express complex I and
were absent from the genomes of the nonaerobic yeasts
S. cerevisiae, C. Glabrata, and K. Lactis. However, the se-
quence of the ten coding exons of the KLHL32 gene was
normal in the patients’ DNA. We next examined the three
exons of the C6ORF66 gene, which has orthologs in insects
but not in fungi (primers available upon request). In the
second exon of this gene, at nucleotide 194 a T/C substi-
tution that predicts a Leu65Pro was detected (Figure 4). All
of the patients in the family whose DNA samples were
available were homozygous for the mutation. The six par-
ents and ﬁve healthy sibs were heterozygous for the muta-
tion, and four healthy sibs were homozygous for the nor-
mal allele. None of the healthy sibs was homozygous for34 The American Journal of Human Genetics 82, 32–38, January 2008
Table 1. Enzymatic Activities in Muscle and Fibroblasts of the Patients
Sample
Tissue Assay Control (n ¼ 50) F359 F434 F511c F334 F72 F528
Muscle
Citrate synthasea 21205 370 1250 1700 710 1750 820
Complex Ia 2745 127 26 (17%) 37 (17%) 5 (5.5%) UL 14 (14%)
Complex IþIIIa 5085 164 40 (14%) 48 (12%) (47%)c 8 (16%) 90 (21%) 40 (21%)
Complex IIþIIIa 3405 84 194 (97%) 408 (150%) 73 (65%) 378 (135%) 156 (119%)
Complex IIa 3275 52 - 298 (114%) 80 (74%) - 209 (170%)
Complex IVb 14.8 5 3.6 7.9 (91%) 12.3 (104%) 3.7 14.0 (115%) 6.5 (113%)
Complex Va 7205 203 507 (123%) 276 (48%) 262 (110%) 421 (71%) 154 (57%)
Fibroblasts
Citrate synthasea 2495 97 327 473 250 - - 328
Complex Ia 31 5 11 13 (32%) 28 (42%) 21 (67%) - - 18 (43%)
Complex IIa 80 5 30 84 (82%) 123 (100%) 82 (103%) - - 72 (68%)
Complex IVa 4125 140 492 (92%) 877 (105%) 547 (132%) - - 489 (86%)
Enzymatic activities in muscle and fibroblasts of the patients. Enzymatic activities are also presented in the brackets as a percentage of the control mean,
normalized for citrate synthase activity. UL denotes under the detection limit.
a nmol/min/mg.
b Velocity constant.
c Measured by another laboratory.the mutation. A BLAST search showed that the mutation
was not present in any reported human expressed-se-
quence tag (EST), nor was it found in 122 ethnic-matched
controls.
Figure 3. Blue Native Acrylamide-Gel Electrophoresis of
Muscle Mitochondria
Equal amount of citrate synthase activity (12 mU) was loaded in
each lane. Left lane shows the patient, and right lane shows the
control. The five enzymatic complexes, identified by Rf, are indi-
cated by the arrows on the right side. The two smaller intermedi-
ates, which appear only in the patient sample, are indicated by
the arrows on the left side.ThOf the 20 consanguineous families of patients with iso-
lated complex I deﬁciency who were subjected to homozy-
gosity mapping, we identiﬁed the same mutation in the
C6ORF66 gene in one family. The patient (F434) was the
second born to ﬁrst cousins of Arab-Muslim origin. Fetal
echocardiography at the 33rd gestational week revealed di-
lated cardiomyopathy, more prominent on the right, with
reduced contractility of the two ventricles (shortening
fraction [SF] ¼ 28%). The patient was delivered at 37 weeks
but had low birth weight (1970 g); the physical examina-
tion was unremarkable apart from a grade 2/6 systolic
murmur, which was heard all over the precordium. Echo-
cardiography revealed right-ventricular hypertrophy of
moderate severity with moderate tricuspid regurgitation.
At 14 hr of age, he developed bradycardia and hypotension
due to poor myocardial contractility accompanied by se-
vere metabolic acidosis and hyperammonemia. There
was no response to vasopressors, and the patient expired
at 24 hr of age. Pathological examination of the liver and
myocardium revealed microvesicular fatty inﬁltration. In
mitochondria isolated from the skeletal muscle and ﬁbro-
blasts, isolated complex I deﬁciency was detected (Table
1). In repeated interview, the parents’ common grand-
mother recalled that her grandmother was born in the
same village where members of the large pedigree still
reside.
C6ORF66 was initially cloned from the rat Nb2 T lym-
phoma cell line.15 The gene encodes 175 amino acids,
which form a 20.2 kDa protein. The Leu65 is conserved
from D. melanogaster to humans (Figure 4) and resides
within a putative calmodulin-binding domain that spans
residues 54–74; nonetheless, only a small fraction of the
protein was previously shown to bind calmodulin in a
Ca2þ-dependent manner.16e American Journal of Human Genetics 82, 32–38, January 2008 35
To testwhether themutatedC6ORF66 gene is the cause of
complex I deﬁciency in our patients, we transfected their
cellswith thewild-type cDNAofC6ORF66. Following trans-
fection, the mRNA ratio of C6ORF66:beta-actin was dou-
bled (Figure 5A). The C6ORF66:beta-actin mRNA ratio was
unchanged in patients’ cells transfected with the empty
vector. Concomitantly, NADH:ubiquinone reductase activ-
ity in isolated mitochondria from the patient cells had
normalized, whereas cells transfected with the empty vec-
tor remained deﬁcient (Figure 5B). Complex IV activity
was not altered by the transfection (Figure 5C). The results
clearly establish the importance of C6ORF66 for complex
I activity.
Finally, we have produced antibodies to the C6ORF66
protein and studied its subcellular localization. Cytosolic
and mitochondrial fractions from control ﬁbroblasts were
prepared and analyzed by western blot. This analysis re-
Figure 4. The T194C Mutation Is Shown
in the Patient DNA, in Control DNA, and
in an Obligate Heterozygote DNA
The T194C mutation is shown (arrow) in
the DNA samples of a patient (A), a healthy
control (B), and an obligate heterozygote
(C). Conservation from D. melanogaster to
humans is shown in the table where the
mutated codon Leu65 is bordered by bold
lines.
Figure 5. C6ORF66 cDNA Transfection
in Fibroblasts
(A) The ratio of C6ORF66:beta-actin mRNA.
(B) The ratio of complex I:citrate synthase
activity.
(C) The ratio of complex IV:citrate syn-
thase activity (divided by 10).
Black bars represent the patient, hatched
bars represent patient cells transfected
with an empty vector, white bars represent
patient cells transfected with the C6ORF66
cDNA-containing vector, and gray bars
represent control cells. Results are pre-
sented as mean of quadruplicate determi-
nations 5 standard deviation, analyzed
by Student’s t test.
vealed that the C6ORF66 protein is
localized to the mitochondria
(Figure 6A). In isolated mitochondria
from the muscle of patients F434
and F359, the ratio of the
C6ORF66:PDH-E1-alpha proteins
was 0.12 5 0.006 and 0.39 5 0.02
(control 0.67–0.72). The difference
between patients and controls was
signiﬁcant: p < 0.005 (Figure 6B and
6C). Although the different protein
levels in the two patients could be the result of a variability
at the level of the regulatory factors responsible for the
steady state of the mutant protein, this ﬁnding neverthe-
less indicates that the mutation affects the level of the
C6ORF66 protein.
Discussion
We describe six patients who presented in infancy
with devastating encephalomyopathy or antenatal cardio-
myopathy, attributed to deﬁciency of complex I of the mi-
tochondrial respiratory chain. Using homozygosity map-
ping, we identiﬁed in the C6ORF66 gene a missense
mutation that affected a conserved residue and was associ-
ated with a reduction of the mRNA level in ﬁbroblasts and
a signiﬁcant decrease of the C6ORF66 protein in muscle.
The dysfunction of complex I was the direct consequence36 The American Journal of Human Genetics 82, 32–38, January 2008
Figure 6. The C6ORF66 Subcellular
Localization in Fibroblasts and Its Con-
tent in Muscle Mitochondria
(A) Western-blot analysis of the cytosolic
(lane 1) and mitochondrial (lane 2) frac-
tions of control fibroblasts with antibodies
against C6ORF66, tubulin, and PDH-E1-
alpha proteins.
(B) Western-blot analysis of the mitochon-
drial fractions from muscle of control (lanes
1 and 2) and patients (lane 3, patient F434;
lane4, patient F359) with antibodies against
C6ORF66 and PDH-E1-alpha proteins.
(C) Anti-C6ORF66:anti-E1-alpha ratio cal-
culated with density analysis of the western
blot shown in (B). Numbers of bars are as
in (B).
Results are presented as mean5 standard
deviation.of the mutation in the C6ORF66 gene, as demonstrated
by the functional restoration of complex I activity upon
transfection of the patients’ cells with the wild-type cDNA.
Complex I has an L-shaped structure that consists of a
hydrophobic arm, which contains the seven mitochon-
drial encoded subunits and is embedded in the lipid mem-
brane, and a hydrophilic, peripheral arm, which contains
the iron-sulfor clusters and protrudes into the matrix.
The assembly process of this 900 kDa complex and the fac-
tors that participate in it are largely unknown. Clearly, this
is a stepwise process with seven intermediary subcom-
plexes shared by two assembly pathways: de novo synthe-
sis headed by the mitochondrial encoded subunits, and re-
generation of existing complexes by exchange of already
integrated subunits with newly imported ones.17,18
Heretofore, three assembly factors have been identiﬁed
in humans: NDUFA12L, which plays a role at a late stage
of complex I biogenesis;8 NDUFAF1, which is essential
for the integration of complex I subunits into early assem-
bly intermediates;9 and Ecsit, which interacts with the
NDUFAF1 protein.19
Using C6ORF66 antibodies, we have shown that the
C6ORF66 protein is found within the mitochondria. The
ﬁrst 34 residues of the protein are predicted by the TargetP
software to form the mitochondrial-targeting sequence.
The fact that a mutation in the gene is associated with
reduction of the mature complex I form in muscle of the
patients yet the protein is not part of the ﬁnal complex
structure is indicative of its importance for complex I bio-
genesis, suggesting that C6ORF66 is a novel complex I
assembly factor.
The C6ORF66 gene product was previously demon-
strated to promote breast cell cancer invasiveness by induc-
ing the excretion of the extracellular-matrix-degrading en-
zyme MMP-9.16 The involvement of a complex I assemblyThfactor in tumorigenesis is unexpected because it is gener-
ally accepted that cancer cells preferentially use ‘‘aerobic
glycolysis,’’ i.e., they convert glucose to lactate in the pres-
ence of oxygen (Warburg effect).20 This is mainly done by
enhancing glucose supply, increasing the expression of
glycolysis genes, and inhibiting the pyruvate dehydroge-
nase complex.21 Although there is considerable evidence
to support the Warburg effect, there are no data to suggest
that mitochondrial respiration is less active in cancer cells
than in normal cells. Furthermore, the Warburg effect is
inconsistent with the fact that activation of Myc oncogene
is associated with increased mitochondrial biogenesis and
respiration.22 The ﬁnding that the pro-oncogenicC6ORF66
is essential for the normal function of the mitochondrial
respiratory chain may therefore support a role for mito-
chondrial respiration in tumorigenesis. Interestingly, the
assembly factor NDUFA12L was identiﬁed in a screen of
transcriptional targets of c-myc. Furthermore, knocking
down NDUFA12L by RNAi inhibited tumorigenesis.23
Whether the pro-oncogenic effect is mediated via the cel-
lular requirement for complex I activity or is an entirely
separate process is a matter of conjecture. Dual roles have
been described for the complex I assembly factor Ecsit,
which was primarily identiﬁed in the Toll signaling path-
way and in the BMP pathway.24
In summary, we have identiﬁed C6ORF66 as a novel
complex I assembly factor and described the clinical phe-
notypes associated with a mutation in the gene. Our data
open the way for revisiting the involvement of mitochon-
drial function in tumorigenesis.
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Web Resources
The URLs for data presented herein are as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.
nlm.nih.gov/Omim/ (for NADH:ubiquinone oxidoreductase
[complex I] deﬁciency)
TargetP, http://www.cbs.dtu.dk/services/TargetP/
ImageJ, http://rsb.info.nih.gov/ij/
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